Hit the lentiviral characterization jackpot with accurate RNA detection

Sunday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Hit the lentiviral characterization jackpot with accurate RNA detection

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Getting an early read on the titer of intact, RNA-containing lentivirus in a batch is vital for optimizing cell therapy manufacture. Most current methods work with only the purest samples and cannot check how many viral particles contain both capsid and RNA. This makes it challenging to achieve an accurate lentivirus titer immune to fragmented or damaged viral particles and contaminants.

Leprechaun provides a complete biophysical characterization of individual lentivirus particles from crude harvest to final product. Using <25 µL sample, the platform pairs up single particle sizing with fluorescence microscopy to directly analyze viral particle size, envelope protein, and both capsid and RNA. This gives an accurate titer of structurally complete, RNA-containing lentivirus at every process step.

In this webinar you’ll learn how Leprechaun isolates lentivirus from even the crudest samples, checks each virus for capsid and RNA, and sizes everything up to separate aggregates from single viruses. Multiple lentivirus batches will be explored to show how Leprechaun can help identify high-quality samples and compare samples from different purification stages.

Learn how to perform single particle analysis of lentivirus in crude and pure samples
Discover how to identify at harvest which batches have the highest titer of intact, RNA-containing lentivirus
Learn how to track viral titer, structure, and contamination throughout your purification process

Bhargavi Kondragunta

Director, Internal R&D & Product Development at Catalent Cell and Gene therapy

Bhargavi Kondragunta is currently the Director of Internal R&D & Product Development at Catalent. Prior to Catalent she worked in Biopharma for over 20 years in Process development, CMC, and manufacturing sciences. She has a PhD in Chemical & Biochemical Engineering from UMBC, Maryland, and an M.S. in ChemE from Drexel University, Philadelphia. Most recently she led the process development efforts for Gene therapy vectors at REGENXBIO, and prior to that worked at several Biopharma including BMS, E-Merck, and GSK.